BeStock  
Stocks › Biotechnology › RPRX

Royalty Pharma RPRX

US equityMarket cap rank #641Biotechnology
$68.45 +$0.73 (+1.08%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $67.91 -0.79%
Open$68.17
Prev close$67.72
Day range$67.95 – $68.83
Volume3.53M
Market cap$30.48B
P/E (TTM)44.7
Dividend yield1.35%

RPRX Stock News

Headlines matching Royalty Pharma or the RPRX ticker, most recent first.

  • Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $70Market news · 9 Sep 2026 · Direct mention
  • TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $68 PositiveMarket news · 8 Sep 2026 · Direct mention
  • UBS Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $66Market news · 8 Sep 2026 · Direct mention
  • Royalty Pharma(RPRX.US) Officer Sells US$5.85 Million in Common StockMarket news · 25 Sep 2026 · Direct mention
  • BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Announces Target Price $63Market news · 24 Sep 2026 · Direct mention
  • Form 144 | Royalty Pharma(RPRX.US) Officer Proposes to Sell 5.85 Million in Common StocksMarket news · 23 Sep 2026 · Direct mention
  • Goldman Sachs Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $66 PositiveMarket news · 7 Aug 2026 · Direct mention
  • Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $65Market news · 7 Aug 2026 · Direct mention
  • Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $65 PositiveMarket news · 6 Aug 2026 · Direct mention
  • Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $70 PositiveMarket news · 6 Aug 2026 · Direct mention
  • UBS Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $66 PositiveMarket news · 11 Aug 2026 · Direct mention
  • J.P. Morgan Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $62 PositiveMarket news · 11 Aug 2026 · Direct mention
  • Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $66Market news · 16 Jul 2026 · Direct mention
  • TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $65 PositiveMarket news · 13 Jul 2026 · Direct mention
  • BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy RatingMarket news · 10 Jul 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on RPRX.

Sign in to join the discussion.

Scroll to Top